Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Crizotinib
100%
Anaplastic Lymphoma Kinase
100%
Fusion Variants
100%
Anaplastic Lymphoma Kinase Fusion
100%
Progression-free Survival
62%
EML4
62%
Anaplastic Lymphoma Kinase Rearrangement
50%
Next-generation Sequencing
25%
Duration of Response
25%
Clinical Efficacy
12%
Tumor Protein p53 (TP53)
12%
Median Progression-free Survival
12%
Tumor Specimens
12%
Baseline Characteristics
12%
TP53 mutation
12%
Survival Analysis
12%
No Significant Difference
12%
Long Progression-free Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Anaplastic Lymphoma Kinase
100%
Crizotinib
100%
Progression Free Survival
53%
Neoplasm
7%
Biochemistry, Genetics and Molecular Biology
Anaplastic Lymphoma Kinase
100%
Crizotinib
100%
Progression Free Survival
53%
EML4
38%
Next Generation Sequencing
15%
Wild Type
7%